Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 9,414 | Dovepress* | 8,479+ | 955 | 9,434 | |
| PubMed Central* | 935 | 234 | 1,169 | ||
| Totals | 9,414 | 1,189 | 10,603 | ||
| *Since 30 November 2016 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 | 2 |
View citations on PubMed and Google Scholar